Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lncRNA SLC7A11-AS1 as stomach cancer drug-resistance diagnosis marker

A diagnostic marker, gastric cancer drug resistance technology, applied in the field of medical biological detection, can solve the problems of low survival rate of gastric cancer patients, and achieve the effect of good translational medicine prospects, good specificity and high sensitivity

Active Publication Date: 2019-12-24
成都医学院第一附属医院
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the diagnosis and treatment technology is constantly improving, the survival rate of gastric cancer patients is still very low, mainly because most patients are diagnosed in the middle and advanced stages

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lncRNA SLC7A11-AS1 as stomach cancer drug-resistance diagnosis marker
  • Application of lncRNA SLC7A11-AS1 as stomach cancer drug-resistance diagnosis marker
  • Application of lncRNA SLC7A11-AS1 as stomach cancer drug-resistance diagnosis marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] The cell viability of the cisplatin-resistant gastric cancer cell line SGC-7901 / DDP and the non-drug-resistant gastric cancer cell line SGC-7901 were tested at different cisplatin (DDP) concentrations, and observed by electron microscopy. The results are as follows: figure 1 and figure 2 shown. It can be seen that the cell activity of SGC-7901 / DDP is higher than that of SGC-7901 in the same concentration of DDP, and the IC50 of SGC-7901 / DDP is also higher than that of SGC-7901.

Embodiment 2

[0080] The expression levels of lncRNA SLC7A11-AS1 in the cisplatin-resistant gastric cancer cell line SGC-7901 / DDP and the non-drug-resistant gastric cancer cell line SGC-7901 were determined, and the results were as follows: image 3 shown. It can be seen that SLC7A11-AS1 and SLC7A11 are involved in the drug resistance of gastric cancer cells to cisplatin.

Embodiment 3

[0082] The cisplatin-resistant gastric cancer cell line SGC-7901 / DDP and the non-drug-resistant gastric cancer cell line SGC-7901 were respectively infected with adenovirus and observed by electron microscope. The results are as follows: Figure 4 and Figure 5 shown. Under adenovirus infection, SLC7A11-AS1 was down-regulated, and the cell viability increased after down-regulation of SLC7A11-AS1, which shows that SLC7A11-AS1 is involved in the resistance of gastric cancer cells to cisplatin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of lncRNA SLC7A11-AS1 as a stomach cancer drug-resistance diagnosis marker and relates to the technical field of medical biological detection. The invention provides application of the lncRNA SLC7A11-AS1 as the stomach cancer drug-resistance diagnosis marker. The invention also constructs a stomach cancer drug-resistance diagnosis marker or kit containing a pairof specific detection primers to detect tissue specimens or blood samples such as plasma, serum and blood platelets. The lncRNA SLC7A11-AS1 has good clinical application values and has better detection effects on stomach cancer drug-resistance diagnosis.

Description

technical field [0001] The invention belongs to the technical field of medical biological detection, and in particular relates to the application of lncRNA SLC7A11-AS1 as a diagnostic marker for gastric cancer drug resistance. Background technique [0002] China is one of the countries with the highest incidence rate of gastric cancer. The new cases of gastric cancer account for more than 40% of the world. Gastric cancer is the third cause of malignant tumor mortality. In recent years, with the continuous improvement of diagnosis and treatment technology, although the mortality rate of gastric cancer has decreased and the prognosis has improved significantly, the 5-year survival rate of gastric cancer in large medical centers in my country has increased significantly. But relative to the Japanese data, there is still a considerable gap. How to effectively improve the diagnosis and treatment of gastric cancer has always been a hot and difficult issue for clinicians. Althoug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/113
CPCC12Q1/6886C12Q2600/178C12Q2600/158C12Q2600/106Y02A50/30
Inventor 肖江卫罗雅军黄清梅刘紫麟叶鹏程姚林向万平
Owner 成都医学院第一附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com